Novel regulatory functions for Toll-like receptor-activated B cells during intracellular bacterial infection

Immunological Reviews

Volumn 240, Issue 1, 2011, Pages 52-71

  Fillatreau, Simon ^a  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

B cells; Bacterial Toll like receptors; Cytokines; Inflammation

Indexed keywords

IMMUNOLOGIC AGENT; INTERLEUKIN 10; TOLL LIKE RECEPTOR; VACCINE;

ANTIBODY PRODUCING CELL; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BACTERIAL INFECTION; CELLULAR IMMUNITY; CYTOKINE RELEASE; HOST RESISTANCE; HUMAN; IMMUNOTHERAPY; INFECTION PREVENTION; INNATE IMMUNITY; INTRACELLULAR BACTERIUM; PRIMARY INFECTION; PRIORITY JOURNAL; REVIEW; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SECONDARY INFECTION; T LYMPHOCYTE; VACCINATION;

B-LYMPHOCYTES; BACTERIAL INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; TOLL-LIKE RECEPTORS;

EID: 79951915895     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2010.00991.x     Document Type: Review

References (203)

1. Barr TA, Brown S, Mastroeni P, Gray D. TLR and B cell receptor signals to B cells differentially program primary and memory Th1 responses to Salmonella enterica. J Immunol 2010;185:2783-2789.
2. Kondratieva TK, Rubakova EI, Linge IA, Evstifeev VV, Majorov KB, Apt AS. B cells delay neutrophil migration toward the site of stimulus: tardiness critical for effective bacillus Calmette-Guerin vaccination against tuberculosis infection in mice. J Immunol 2010;184:1227-1234.
3. Neves P, et al. MyD88-signaling in B cells suppresses protective immunity during Salmonella typhimurium infection. Immunity 2010;33:777-790.
4. Jendholm J, et al. Superantigen- and TLR-dependent activation of tonsillar B cells after receptor-mediated endocytosis. J Immunol 2009;182:4713-4720.
5. Castro-Eguiluz D, Pelayo R, Rosales-Garcia V, Rosales-Reyes R, Alpuche-Aranda C, Ortiz-Navarrete V. B cell precursors are targets for Salmonella infection. Microb Pathog 2009;47:52-56.
6. Rosales-Reyes R, Alpuche-Aranda C, Ramirez-Aguilar Mde L, Castro-Eguiluz AD, Ortiz-Navarrete V. Survival of Salmonella enterica serovar typhimurium within late endosomal-lysosomal compartments of B lymphocytes is associated with the inability to use the vacuolar alternative major histocompatibility complex class I antigen-processing pathway. Infect Immun 2005;73:3937-3944.
7. McElroy DS, Ashley TJ, D'Orazio SE. Lymphocytes serve as a reservoir for Listeria monocytogenes growth during infection of mice. Microb Pathog 2009;46:214-221.
8. Seki E, et al. Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice. J Immunol 2002;169:3863-3868.
9. Weiss DS, Raupach B, Takeda K, Akira S, Zychlinsky A. Toll-like receptors are temporally involved in host defense. J Immunol 2004;172:4463-4469.
10. Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991;350:423-426.
11. Chen J, et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol 1993;5:647-656.
12. Gu H, Zou YR, Rajewsky K. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 1993;73:1155-1164.
13. Ngo VN, Cornall RJ, Cyster JG. Splenic T zone development is B cell dependent. J Exp Med 2001;194:1649-1660.
14. Golovkina TV, Shlomchik M, Hannum L, Chervonsky A. Organogenic role of B lymphocytes in mucosal immunity. Science 1999;286:1965-1968.
15. Fu YX, Huang G, Wang Y, Chaplin DD. B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion. J Exp Med 1998;187:1009-1018.
16. Joao C, Ogle BM, Gay-Rabinstein C, Platt JL, Cascalho M. B cell-dependent TCR diversification. J Immunol 2004;172:4709-4716.
17. Longbottom D, Livingstone M. Vaccination against chlamydial infections of man and animals. Vet J 2006;171:263-275.
18. Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005;5:149-161.
19. Rodolakis A, Salinas J, Papp J. Recent advances on ovine chlamydial abortion. Vet Res 1998;29:275-288.
20. Yang X, Brunham RC. Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. J Immunol 1998;161:1439-1446.
21. Peeling R, Maclean IW, Brunham RC. In vitro neutralization of Chlamydia trachomatis with monoclonal antibody to an epitope on the major outer membrane protein. Infect Immun 1984;46:484-488.
22. Buendia AJ, et al. B-cell-deficient mice show an exacerbated inflammatory response in a model of Chlamydophila abortus infection. Infect Immun 2002;70:6911-6918.
23. Esmon CT, et al. Inflammation, sepsis, and coagulation. Haematologica 1999;84:254-259.
24. Leist M, Gantner F, Bohlinger I, Tiegs G, Germann PG, Wendel A. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am J Pathol 1995;146:1220-1234.
25. Johansson M, Ward M, Lycke N. B-cell-deficient mice develop complete immune protection against genital tract infection with Chlamydia trachomatis. Immunology 1997;92:422-428.
26. Su H, Feilzer K, Caldwell HD, Morrison RP. Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice. Infect Immun 1997;65:1993-1999.
27. Buendia AJ, et al. B Cells are essential for moderating the inflammatory response and controlling bacterial multiplication in a mouse model of vaccination against Chlamydophila abortus infection. Infect Immun 2009;77:4868-4876.
28. Moore T, et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 2002;105:213-221.
29. Morrison SG, Morrison RP. Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect Immun 2001;69:2643-2649.
30. Morrison SG, Su H, Caldwell HD, Morrison RP. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect Immun 2000;68:6979-6987.
31. Morrison RP, Feilzer K, Tumas DB. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect Immun 1995;63:4661-4668.
32. Johansson M, Lycke N. Immunological memory in B-cell-deficient mice conveys long-lasting protection against genital tract infection with Chlamydia trachomatis by rapid recruitment of T cells. Immunology 2001;102:199-208.
33. Tarnvik A. Nature of protective immunity to Francisella tularensis. Rev Infect Dis 1989;11:440-451.
34. Wiener SL. Strategies for the prevention of a successful biological warfare aerosol attack. Mil Med 1996;161:251-256.
35. Dennis DT, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001;285:2763-2773.
36. Anthony LS, Kongshavn PA. Experimental murine tularemia caused by Francisella tularensis, live vaccine strain: a model of acquired cellular resistance. Microb Pathog 1987;2:3-14.
37. Sandstrom G. The tularaemia vaccine. J Chem Technol Biotechnol 1994;59:315-320.
38. Telepnev M, Golovliov I, Grundstrom T, Tarnvik A, Sjostedt A. Francisella tularensis inhibits Toll-like receptor-mediated activation of intracellular signalling and secretion of TNF-alpha and IL-1 from murine macrophages. Cell Microbiol 2003;5:41-51.
39. Hajjar AM, et al. Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptors. Infect Immun 2006;74:6730-6738.
40. Rahhal RM, Vanden Bush TJ, McLendon MK, Apicella MA, Bishop GA. Differential effects of Francisella tularensis lipopolysaccharide on B lymphocytes. J Leukoc Biol 2007;82:813-820.
41. Elkins KL, Winegar RK, Nacy CA, Fortier AH. Introduction of Francisella tularensis at skin sites induces resistance to infection and generation of protective immunity. Microb Pathog 1992;13:417-421.
42. Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun 1991;59:2922-2928.
43. Elkins KL, Bosio CM, Rhinehart-Jones TR. Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun 1999;67:6002-6007.
44. Stenmark S, Lindgren H, Tarnvik A, Sjostedt A. Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica. Microb Pathog 2003;35:73-80.
45. Bosio CM, Elkins KL. Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity. Infect Immun 2001;69:194-203.
46. Elkins KL, Leiby DA, Winegar RK, Nacy CA, Fortier AH. Rapid generation of specific protective immunity to Francisella tularensis. Infect Immun 1992;60:4571-4577.
47. Elkins KL, Rhinehart-Jones T, Nacy CA, Winegar RK, Fortier AH. T-cell-independent resistance to infection and generation of immunity to Francisella tularensis. Infect Immun 1993;61:823-829.
48. Cole LE, et al. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci USA 2009;106:4343-4348.
49. Green SJ, et al. Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun 1993;61:689-698.
50. Elkins KL, MacIntyre AT, Rhinehart-Jones TR. Nonspecific early protective immunity in Francisella and Listeria infections can be dependent on lymphocytes. Infect Immun 1998;66:3467-3469.
51. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996;93:2879-2883.
52. Krocova Z, et al. Interaction of B cells with intracellular pathogen Francisella tularensis. Microb Pathog 2008;45:79-85.
53. Li J, et al. B lymphocytes from early vertebrates have potent phagocytic and microbicidal abilities. Nat Immunol 2006;7:1116-1124.
54. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19:93-129.
55. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009;27:393-422.
56. Bean AG, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999;162:3504-3511.
57. Ulrichs T, et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004;204:217-228.
58. Tsai MC, et al. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 2006;8:218-232.
59. Maglione PJ, Xu J, Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J Immunol 2007;178:7222-7234.
60. Vordermeier HM, Venkataprasad N, Harris DP, Ivanyi J. Increase of tuberculous infection in the organs of B cell-deficient mice. Clin Exp Immunol 1996;106:312-316.
61. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008;46:1738-1740.
62. Berry MP, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-977.
63. Turner J, Frank AA, Brooks JV, Gonzalez-Juarrero M, Orme IM. The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin-4. Exp Gerontol 2001;36:537-545.
64. Manca C, et al. Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol 1999;162:6740-6746.
65. Greenaway C, Lienhardt C, Adegbola R, Brusasca P, McAdam K, Menzies D. Humoral response to Mycobacterium tuberculosis antigens in patients with tuberculosis in the Gambia. Int J Tuberc Lung Dis 2005;9:1112-1119.
66. Schrier DJ, Sternick JL, Allen EM, Moore VL. Immunogenetics of BCG-induced anergy in mice: control by genes linked to the Igh complex. J Immunol 1982;128:1466-1469.
67. Sternick JL, Schrier DJ, Moore VL. Genetic control of BCG-induced granulomatous inflammation in mice. Exp Lung Res 1983;5:217-228.
68. Bothamley GH, Rudd R, Festenstein F, Ivanyi J. Clinical value of the measurement of Mycobacterium tuberculosis specific antibody in pulmonary tuberculosis. Thorax 1992;47:270-275.
69. Hypogammaglobulinaemia in the United Kingdom. Summary report of a Medical Research Council working-party. Lancet 1969;1:163-168.
70. Maglione PJ, Xu J, Casadevall A, Chan J. Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol 2008;180:3329-3338.
71. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006;24:19-28.
72. Turner J, et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol 2002;169:6343-6351.
73. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002;195:1653-1659.
74. Dhodapkar KM, et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci USA 2005;102:2910-2915.
75. Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines 2004;3:23-34.
76. Mittrucker HW, Kaufmann SH. Immune response to infection with Salmonella typhimurium in mice. J Leukoc Biol 2000;67:457-463.
77. Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 2007;25:7848-7857.
78. DeRoeck D, Jodar L, Clemens J. Putting typhoid vaccination on the global health agenda. N Engl J Med 2007;357:1069-1071.
79. Steinberg EB, et al. Typhoid fever in travelers: who should be targeted for prevention? Clin Infect Dis 2004;39:186-191.
80. Michel R, Garnotel E, Spiegel A, Morillon M, Saliou P, Boutin JP. Outbreak of typhoid fever in vaccinated members of the French Armed Forces in the Ivory Coast. Eur J Epidemiol 2005;20:635-642.
81. Froeschle JE, Decker MD. Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever. Vaccine 2010;28:1451-1453.
82. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996;14:435-438.
83. Keddy KH, Klugman KP, Hansford CF, Blondeau C, Bouveret le Cam NN. Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization. Vaccine 1999;17:110-113.
84. Russmann H, Shams H, Poblete F, Fu Y, Galan JE, Donis RO. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 1998;281:565-568.
85. Zhang XL, Jeza VT, Pan Q. Salmonella typhi: from a human pathogen to a vaccine vector. Cell Mol Immunol 2008;5:91-97.
86. Tam MA, Rydstrom A, Sundquist M, Wick MJ. Early cellular responses to Salmonella infection: dendritic cells, monocytes, and more. Immunol Rev 2008;225:140-162.
87. Salcedo SP, Noursadeghi M, Cohen J, Holden DW. Intracellular replication of Salmonella typhimurium strains in specific subsets of splenic macrophages in vivo. Cell Microbiol 2001;3:587-597.
88. Sheppard M, et al. Dynamics of bacterial growth and distribution within the liver during Salmonella infection. Cell Microbiol 2003;5:593-600.
89. Hess J, Ladel C, Miko D, Kaufmann SH. Salmonella typhimurium aroA- infection in gene-targeted immunodeficient mice: major role of CD4+ TCR-alpha beta cells and IFN-gamma in bacterial clearance independent of intracellular location. J Immunol 1996;156:3321-3326.
90. Brown A, Hormaeche CE. The antibody response to salmonellae in mice and humans studied by immunoblots and ELISA. Microb Pathog 1989;6:445-454.
91. Singh SP, Williams YU, Klebba PE, Macchia P, Miller S. Immune recognition of porin and lipopolysaccharide epitopes of Salmonella typhimurium in mice. Microb Pathog 2000;28:157-167.
92. Cunningham AF, et al. Salmonella induces a switched antibody response without germinal centers that impedes the extracellular spread of infection. J Immunol 2007;178:6200-6207.
93. Mastroeni P, Simmons C, Fowler R, Hormaeche CE, Dougan G. Igh-6(-/-) (B-cell-deficient) mice fail to mount solid acquired resistance to oral challenge with virulent Salmonella enterica serovar typhimurium and show impaired Th1 T-cell responses to Salmonella antigens. Infect Immun 2000;68:46-53.
94. Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981;291:238-239.
95. Mittrucker HW, Raupach B, Kohler A, Kaufmann SH. Cutting edge: role of B lymphocytes in protective immunity against Salmonella typhimurium infection. J Immunol 2000;164:1648-1652.
96. McSorley SJ, Jenkins MK. Antibody is required for protection against virulent but not attenuated Salmonella enterica serovar typhimurium. Infect Immun 2000;68:3344-3348.
97. Michetti P, et al. Monoclonal immunoglobulin A prevents adherence and invasion of polarized epithelial cell monolayers by Salmonella typhimurium. Gastroenterology 1994;107:915-923.
98. Mastroeni P, Villarreal-Ramos B, Hormaeche CE. Role of T cells, TNF alpha and IFN gamma in recall of immunity to oral challenge with virulent salmonellae in mice vaccinated with live attenuated aro-Salmonella vaccines. Microb Pathog 1992;13:477-491.
99. Ugrinovic S, Menager N, Goh N, Mastroeni P. Characterization and development of T-Cell immune responses in B-cell-deficient (Igh-6(-/-)) mice with Salmonella enterica serovar typhimurium infection. Infect Immun 2003;71:6808-6819.
100. Verjans GM, Ringrose JH, van Alphen L, Feltkamp TE, Kusters JG. Entrance and survival of Salmonella typhimurium and Yersinia enterocolitica within human B- and T-cell lines. Infect Immun 1994;62:2229-2235.
101. Souwer Y, et al. B cell receptor-mediated internalization of Salmonella: a novel pathway for autonomous B cell activation and antibody production. J Immunol 2009;182:7473-7481.
102. Knodler LA, Finlay BB, Steele-Mortimer O. The Salmonella effector protein SopB protects epithelial cells from apoptosis by sustained activation of Akt. J Biol Chem 2005;280:9058-9064.
103. Freitag NE, Port GC, Miner MD. Listeria monocytogenes- from saprophyte to intracellular pathogen. Nat Rev Microbiol 2009;7:623-628.
104. Pamer EG. Immune responses to Listeria monocytogenes. Nat Rev Immunol 2004;4:812-823.
105. McGregor DD, Koster FT, Mackaness GB. The short lived small lymphocyte as a mediator of cellular immunity. Nature 1970;228:855-856.
106. Ladel CH, Flesch IE, Arnoldi J, Kaufmann SH. Studies with MHC-deficient knock-out mice reveal impact of both MHC I- and MHC II-dependent T cell responses on Listeria monocytogenes infection. J Immunol 1994;153:3116-3122.
107. Matsuzaki G, Vordermeier HM, Hashimoto A, Nomoto K, Ivanyi J. The role of B cells in the establishment of T cell response in mice infected with an intracellular bacteria, Listeria monocytogenes. Cell Immunol 1999;194:178-185.
108. Shen H, Whitmire JK, Fan X, Shedlock DJ, Kaech SM, Ahmed R. A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes. J Immunol 2003;170:1443-1451.
109. Berche P, et al. Detection of anti-listeriolysin O for serodiagnosis of human listeriosis. Lancet 1990;335:624-627.
110. Edelson BT, Unanue ER. Intracellular antibody neutralizes Listeria growth. Immunity 2001;14:503-512.
111. Menon A, Shroyer ML, Wampler JL, Chawan CB, Bhunia AK. In vitro study of Listeria monocytogenes infection to murine primary and human transformed B cells. Comp Immunol Microbiol Infect Dis 2003;26:157-174.
112. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006;6:173-182.
113. Seiler P, Aichele P, Raupach B, Odermatt B, Steinhoff U, Kaufmann SH. Rapid neutrophil response controls fast-replicating intracellular bacteria but not slow-replicating Mycobacterium tuberculosis. J Infect Dis 2000;181:671-680.
114. He B, et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006;176:3931-3941.
115. Rappocciolo G, et al. DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS Pathog 2006;2:e70.
116. Gururajan M, Jacob J, Pulendran B. Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS ONE 2007;2:e863.
117. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944-950.
118. Fillatreau S, Gray D. T cell accumulation in B cell follicles is regulated by dendritic cells and is independent of B cell activation. J Exp Med 2003;197:195-206.
119. Seibert SA, Mex P, Kohler A, Kaufmann SH, Mittrucker HW. TLR2-, TLR4- and Myd88-independent acquired humoral and cellular immunity against Salmonella enterica serovar typhimurium. Immunol Lett 2010;127:126-134.
120. Lampropoulou V, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol 2008;180:4763-4773.
121. Hoehlig K, et al. Immune regulation by B cells and antibodies a view towards the clinic. Adv Immunol 2008;98:1-38.
122. Rousset F, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-1893.
123. Rafei M, et al. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med 2009;15:1038-1045.
124. Ho F, Lortan JE, MacLennan IC, Khan M. Distinct short-lived and long-lived antibody-producing cell populations. Eur J Immunol 1986;16:1297-1301.
125. Palanivel V, Posey C, Horauf AM, Solbach W, Piessens WF, Harn DA. B-cell outgrowth and ligand-specific production of IL-10 correlate with Th2 dominance in certain parasitic diseases. Exp Parasitol 1996;84:168-177.
126. Ronet C, et al. Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production. J Immunol 2010;184:886-894.
127. Velupillai P, Garcea RL, Benjamin TL. Polyoma virus-like particles elicit polarized cytokine responses in APCs from tumor-susceptible and -resistant mice. J Immunol 2006;176:1148-1153.
128. Anderton SM, Fillatreau S. Activated B cells in autoimmune diseases: the case for a regulatory role. Nat Clin Pract Rheumatol 2008;4:657-666.
129. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008;8:391-397.
130. Swanson RN, O'Brien AD. Genetic control of the innate resistance of mice to Salmonella typhimurium: Ity gene is expressed in vivo by 24hours after infection. J Immunol 1983;131:3014-3020.
131. Nnalue NA, Shnyra A, Hultenby K, Lindberg AA. Salmonella choleraesuis and Salmonella typhimurium associated with liver cells after intravenous inoculation of rats are localized mainly in Kupffer cells and multiply intracellularly. Infect Immun 1992;60:2758-2768.
132. Richter-Dahlfors A, Buchan AM, Finlay BB. Murine salmonellosis studied by confocal microscopy: Salmonella typhimurium resides intracellularly inside macrophages and exerts a cytotoxic effect on phagocytes in vivo. J Exp Med 1997;186:569-580.
133. Wang XM, Lin FR, Hsu HS, Mumaw VR, Nakoneczna I. Electronmicroscopic studies on the location of Salmonella proliferation in the murine spleen. J Med Microbiol 1988;25:41-47.
134. Schafer R, Eisenstein TK. Natural killer cells mediate protection induced by a Salmonella aroA mutant. Infect Immun 1992;60:791-797.
135. Hormaeche CE, Mastroeni P, Arena A, Uddin J, Joysey HS. T cells do not mediate the initial suppression of a Salmonella infection in the RES. Immunology 1990;70:247-250.
136. Jouanguy E, Doffinger R, Dupuis S, Pallier A, Altare F, Casanova JL. IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Curr Opin Immunol 1999;11:346-351.
137. Kirby AC, Yrlid U, Wick MJ. The innate immune response differs in primary and secondary Salmonella infection. J Immunol 2002;169:4450-4459.
138. Unanue ER. Inter-relationship among macrophages, natural killer cells and neutrophils in early stages of Listeria resistance. Curr Opin Immunol 1997;9:35-43.
139. Ma X, et al. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med 1996;183:147-157.
140. Collart MA, Belin D, Vassalli JD, de Kossodo S, Vassalli P. Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J Exp Med 1986;164:2113-2118.
141. Bancroft GJ, Sheehan KC, Schreiber RD, Unanue ER. Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. J Immunol 1989;143:127-130.
142. Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 1993;90:3725-3729.
143. Weinstein DL, Lissner CR, Swanson RN, O'Brien AD. Macrophage defect and inflammatory cell recruitment dysfunction in Salmonella susceptible C3H/HeJ mice. Cell Immunol 1986;102:68-77.
144. Rydstrom A, Wick MJ. Monocyte and neutrophil recruitment during oral Salmonella infection is driven by MyD88-derived chemokines. Eur J Immunol 2009;39:3019-3030.
145. O'Brien AD, Rosenstreich DL, Scher I, Campbell GH, MacDermott RP, Formal SB. Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene. J Immunol 1980;124:20-24.
146. Matsumura H, Onozuka K, Terada Y, Nakano Y, Nakano M. Effect of murine recombinant interferon-gamma in the protection of mice against Salmonella. Int J Immunopharmacol 1990;12:49-56.
147. Smelt SC, Cotterell SE, Engwerda CR, Kaye PM. B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology. J Immunol 2000;164:3681-3688.
148. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-376.
149. Eruslanov EB, et al. Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice. Infect Immun 2005;73:1744-1753.
150. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004;21:733-741.
151. MacLennan IC. Germinal centers. Annu Rev Immunol 1994;12:117-139.
152. Yoshida T, et al. Memory B and memory plasma cells. Immunol Rev 2010;237:117-139.
153. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008;47:401-409.
154. Gupta K, Cooper C. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D 2008;9:137-145.
155. Latz E, Franko J, Golenbock DT, Schreiber JR. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol 2004;172:2431-2438.
156. Cooper CL, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005;19:1473-1479.
157. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003;21:2461-2467.
158. Dhiman N, et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 2008;26:1731-1736.
159. Querec T, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006;203:413-424.
160. Day N, et al. Interleukin receptor-associated kinase (IRAK-4) deficiency associated with bacterial infections and failure to sustain antibody responses. J Pediatr 2004;144:524-526.
161. Guay HM, Andreyeva TA, Garcea RL, Welsh RM, Szomolanyi-Tsuda E. MyD88 is required for the formation of long-term humoral immunity to virus infection. J Immunol 2007;178:5124-5131.
162. Zhou S, et al. Role of MyD88 in route-dependent susceptibility to vesicular stomatitis virus infection. J Immunol 2007;178:5173-5181.
163. Cooper CL, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004;22:3136-3143.
164. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005;438:364-368.
165. Barr TA, Brown S, Mastroeni P, Gray D. B cell intrinsic MyD88 signals drive IFN-gamma production from T cells and control switching to IgG2c. J Immunol 2009;183:1005-1012.
166. Meyer-Bahlburg A, Khim S, Rawlings DJ. B cell intrinsic TLR signals amplify but are not required for humoral immunity. J Exp Med 2007;204:3095-3101.
167. Gargano LM, Moser JM, Speck SH. Role for MyD88 signaling in murine gammaherpesvirus 68 latency. J Virol 2008;82:3853-3863.
168. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-760.
169. Crompton PD, et al. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol 2009;182:3318-3326.
170. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-484.
171. Lampropoulou V, et al. Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. Immunol Rev 2010;233:146-161.
172. Kitano H. Biological robustness. Nat Rev Genet 2004;5:826-837.
173. Dixon DR, Darveau RP. Lipopolysaccharide heterogeneity: innate host responses to bacterial modification of lipid a structure. J Dent Res 2005;84:584-595.
174. Kawasaki K, Ernst RK, Miller SI. Deacylation and palmitoylation of lipid A by Salmonellae outer membrane enzymes modulate host signaling through Toll-like receptor 4. J Endotoxin Res 2004;10:439-444.
175. Trent MS, Stead CM, Tran AX, Hankins JV. Diversity of endotoxin and its impact on pathogenesis. J Endotoxin Res 2006;12:205-223.
176. Guo L, et al. Regulation of lipid A modifications by Salmonella typhimurium virulence genes phoP-phoQ. Science 1997;276:250-253.
177. Kawahara K, Tsukano H, Watanabe H, Lindner B, Matsuura M. Modification of the structure and activity of lipid A in Yersinia pestis lipopolysaccharide by growth temperature. Infect Immun 2002;70:4092-4098.
178. Montminy SW, et al. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat Immunol 2006;7:1066-1073.
179. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 2002;3:354-359.
180. Miller SI, Ernst RK, Bader MW. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol 2005;3:36-46.
181. Alon U. Network motifs: theory and experimental approaches. Nat Rev Genet 2007;8:450-461.
182. Mangan S, Itzkovitz S, Zaslaver A, Alon U. The incoherent feed-forward loop accelerates the response-time of the gal system of Escherichia coli. J Mol Biol 2006;356:1073-1081.
183. Yang KK, et al. Neutrophil influx in response to a peritoneal infection with Salmonella is delayed in lipopolysaccharide-binding protein or CD14-deficient mice. J Immunol 2002;169:4475-4480.
184. Beutler B. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 2009;227:248-263.
185. von Bernuth H, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008;321:691-696.
186. Arpin C, Banchereau J, Liu YJ. Memory B cells are biased towards terminal differentiation: a strategy that may prevent repertoire freezing. J Exp Med 1997;186:931-940.
187. Kin NW, Crawford DM, Liu J, Behrens TW, Kearney JF. DNA microarray gene expression profile of marginal zone versus follicular B cells and idiotype positive marginal zone B cells before and after immunization with Streptococcus pneumoniae. J Immunol 2008;180:6663-6674.
188. Martin F, Kearney JF. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory". Immunol Rev 2000;175:70-79.
189. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008;118:3420-3430.
190. Watanabe R, et al. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol 2010;184:4801-4809.
191. Yang Y, Tung JW, Ghosn EE, Herzenberg LA. Division and differentiation of natural antibody-producing cells in mouse spleen. Proc Natl Acad Sci USA 2007;104:4542-4546.
192. O'Garra A, Howard M. IL-10 production by CD5 B cells. Ann N Y Acad Sci 1992;651:182-199.
193. Sun CM, Deriaud E, Leclerc C, Lo-Man R. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity 2005;22:467-477.
194. Nakashima H, et al. CD22 expression mediates the regulatory functions of peritoneal B-1a cells during the remission phase of contact hypersensitivity reactions. J Immunol 2010;184:4637-4645.
195. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002;16:219-230.
196. Velupillai P, Harn DA. Oligosaccharide-specific induction of interleukin 10 production by B220+ cells from schistosome-infected mice: a mechanism for regulation of CD4+ T-cell subsets. Proc Natl Acad Sci USA 1994;91:18-22.
197. Thomas PG, et al. Maturation of dendritic cell 2 phenotype by a helminth glycan uses a Toll-like receptor 4-dependent mechanism. J Immunol 2003;171:5837-5841.
198. Mangan NE, Fallon RE, Smith P, van Rooijen N, McKenzie AN, Fallon PG. Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. J Immunol 2004;173:6346-6356.
199. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol 2008;64:187-199.
200. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 2007;61:97-108.
201. Leibowitz U, Antonovsky A, Medalie JM, Smith HA, Halpern L, Alter M. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 1966;29:60-68.
202. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-920.
203. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007;13:1365-1368.